Holen Sie sich die Stockscreener-App
10.65
4.72%
0.48
Handel nachbörslich:
10.66
0.010
+0.09%
Schlusskurs vom Vortag:
$10.17
Offen:
$10.17
24-Stunden-Volumen:
142.70K
Relative Volume:
0.53
Marktkapitalisierung:
$391.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.20M
KGV:
-6.8038
EPS:
-1.5653
Netto-Cashflow:
$-43.65M
1W Leistung:
-9.05%
1M Leistung:
+44.31%
6M Leistung:
-39.52%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.815
$10.71
1-Wochen-Bereich:
$9.815
$11.98
52-Wochen-Spanne:
$4.8069
$27.50
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Vergleichen Sie MBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
10.65 | 391.40M | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
MBX Biosciences, Inc. (NYSE:MBX) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
MBX Biosciences Reports Q1 2025 Financial Progress - TipRanks
MBX Biosciences, Inc.: Strong Buy Rating Amid Promising Phase II Data and Robust Financial Position - TipRanks
Stifel maintains MBX Biosciences stock Buy rating, $40 target By Investing.com - Investing.com Nigeria
Stifel maintains MBX Biosciences stock Buy rating, $40 target - Investing.com
MBX Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Wells Fargo & Company MN Purchases Shares of 5,844 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Hypoglycemia Market Poised for Notable Growth by 2032, Fueled - openPR.com
MBX Biosciences Up 28%, Insider Buyers Are Up 19% - simplywall.st
9,106 Shares in MBX Biosciences, Inc. (NYSE:MBX) Bought by JPMorgan Chase & Co. - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Rating of “Buy” from Analysts - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Shares Purchased by Geode Capital Management LLC - Defense World
JMP maintains MBX Biosciences stock $38 target, upbeat on trial data - Investing.com Australia
Companies Like MBX Biosciences (NASDAQ:MBX) Are In A Position To Invest In Growth - Yahoo Finance
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences - The Manila Times
MBX Biosciences Reveals Growth Strategy at Citizens and RBC Healthcare Conferences: Key Updates Coming - Stock Titan
5,593 Shares in MBX Biosciences, Inc. (NYSE:MBX) Acquired by Corebridge Financial Inc. - Defense World
25,000 Shares in MBX Biosciences, Inc. (NYSE:MBX) Acquired by Norges Bank - Defense World
MBX Biosciences, Inc. (NYSE:MBX) Receives $37.40 Consensus Price Target from Brokerages - Defense World
MBX Biosciences initiated at Market Outperform by Citizens - MSN
Director Makes Bold Move with Major MBX Biosciences Stock Purchase - TipRanks
JMP Securities Initiates Coverage of MBX Biosciences (MBX) with Market Outperform Recommendation - Nasdaq
MBX Biosciences: Innovative PEP Platform and Promising Pipeline Drive Buy Rating - TipRanks
MBX Bio stock initiated at Market Outperform by Citizens (MBX) - Seeking Alpha
MBX Biosciences director Pescovitz buys $45,311 in stock By Investing.com - Investing.com Canada
MBX Biosciences director Pescovitz buys $45,311 in stock - Investing.com
MBX Biosciences initiated with an Outperform at Citizens JMP - TipRanks
Citizens JMP sees MBX stock outperform with $38 target - Investing.com
MBX Biosciences adds biotech veteran to board By Investing.com - Investing.com South Africa
MBX Biosciences adds biotech veteran to board - Investing.com Australia
MBX Biosciences Appoints Steve Hoerter to Board - TipRanks
MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors - GlobeNewswire
Charles Schwab Investment Management Inc. Invests $1.72 Million in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Bank of New York Mellon Corp Buys Shares of 23,914 MBX Biosciences, Inc. (NYSE:MBX) - Defense World
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
MBX Biosciences Unveils Next-Gen Peptide Therapies: CEO Presentation at Major Healthcare Conference - Stock Titan
MBX Biosciences Inc Reports Q4 2024 Net Loss of $15.6 Million, S - GuruFocus
MBX Biosciences, Inc.: Promising Outlook with Strong Financials and Key Catalysts - TipRanks
MBX Biosciences reports Q4 EPS (47c), consensus (59c) - MSN
MBX Biosciences stock jumps 5% on clinical trial progress By Investing.com - Investing.com Australia
MBX Biosciences stock jumps 5% on clinical trial progress - Investing.com India
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - marketscreener.com
MBX Biosciences Announces Enrollment Completion in Phase 2 Avail™ Trial of Canvuparatide; Phase 2 Trials for MBX 1416 and IND Filing for MBX 4291 Expected in 2025 - Nasdaq
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - GlobeNewswire
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian
MBX Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
MBX Biosciences Secures 2.5-Year Runway with $262M War Chest for Breakthrough Drug Pipeline - Stock Titan
Insider Buyers At MBX Biosciences Likely Disappointed With 17% Slide - Yahoo Finance
Rhumbline Advisers Purchases New Stake in MBX Biosciences, Inc. (NYSE:MBX) - Defense World
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):